EPA Analysis: "EPA Does Not Have Methods to Estimate How Long [EtO Sterilization] Facilities Might Close"
AdvaMed Says "Patients Can't Afford for the EPA to Sweep Those Concerns Under the Rug," Cites Impact on Medtech Supply Chain
WASHINGTON, D.C. – AdvaMed, the Medtech Association, urges the Environmental Protection Agency (EPA) to heed concerns of medtech supply shortfalls under its proposed requirements on ethylene oxide (EtO) sterilization and consider the effects on patient care.
The EPA's impact analysis of its regulation of EtO sterilization through the National Emission Standards for Hazardous Air Pollutants (NESHAP) cites the potential for medtech shortfalls as facilities implement the new requirements. However, in comments responding to questions in interagency review, the EPA appears to downplay the concern and suggests facility closures to install new equipment would be brief. Because EtO sterilization is at capacity, and a number of medtech devices can be sterilized only with EtO, taking facilities offline even briefly could cause major supply disruptions.
FDA Commissioner Robert Califf said in an April 28 article, "This issue is very much on the forefront for us. We are highly aware of it and we’re engaged in the discussions. I’m very worried."
AdvaMed President and CEO Scott Whitaker said, "As we wrote to President Biden and have stated for years, the medtech industry welcomes updated regulations governing EtO sterilization because our industry is just as committed to employee and community safety as it is to improving and saving patients’ lives. However, EPA on one hand recognizes the challenges its proposals pose for the sterile medical technologies patients depend on. On the other hand, it dismisses or downplays the challenges. Patients can't afford for the EPA to sweep those concerns under the rug. Our ability to serve patients depends on not only innovating medtech but also supplying safe, sterile medtech on time, in abundance, to healthcare providers when and wherever they need it."
The EPA's impact analysis of its NESHAP proposal says:
On whether there has been an assessment of time related to shutdowns and business disruptions, the Agency further responds in its interagency response: "EPA believes that these shutdowns typically last at least a week but may be longer if more work is needed. EPA does not have methods to estimate how long facilities might close or what the lost revenues might be. As such these costs are not included in the cost estimates."
Sterilization facilities requiring new equipment must source the equipment, likely from a limited number of specialty suppliers unequipped to accommodate sudden high demand, install the equipment, and test it to ensure necessary sterility levels. Those factors could cause weeks or months of temporary shutdowns to implement the requirements, hindering sterile medtech supplies and patient care. EtO is used to sterilize 50 percent, or 20 billion, of medical devices in the United States each year. As the EPA notes, EtO sterilizes an estimated 95 percent of all surgical kits.
The thousands of pages of supporting documents, the complexity of the regulations, the shorter than usual timeframe for implementing such regulations (18 months versus three years), an equally complex regulation on handling EtO, and the public health implications of implementation all demand careful consideration.
Earlier, AdvaMed urged the EPA to double the amount of time for public comment on the rule, from 60 days to 120 days. In January, Whitaker wrote to President Biden outlining four principles for the EtO regulations, including the potential threat to patient care if facilities shut down and a call for "technology-neutral solutions" to meet new emissions targets. The medtech industry will comment formally on the proposed regulations.
# # #
News / Ethylene Oxide / Regulatory Affairs
May 25, 2023
AdvaMed, the Medtech Association, today welcomed the U.S. Environmental Protection Agency (EPA) extension of 15 more days for public comment on two proposed updates to regulations governing the use of ethylene oxide (EtO) to sterilize half of all medical technology in the United States each year. Even more time would have been preferable, as the regulations could cause shortfalls of critical medtech supplies, AdvaMed said.
News / Ethylene Oxide
May 5, 2023
News / Ethylene Oxide
April 18, 2023
AdvaMed, the medtech association, today called upon the U.S. Environmental Protection Agency (EPA) to double the time it will allow for public comment on two proposed updates to regulations governing the use of ethylene oxide to sterilize, according to FDA, approximately 20 billion medical technologies in the U.S. annually. The rule that governs emissions from ethylene oxide sterilization plants ("the NESHAP"), by law under the Clean Air Act, should have been updated 17 years ago in 2006.
News / Ethylene Oxide
April 11, 2023
The Environmental Protection Agency (EPA) today released its proposed rule regulating ethylene oxide (EtO) sterilizers of medical technology and other commercial uses through the National Emission Standards for Hazardous Air Pollutants (NESHAP) under the Clean Air Act. Scott Whitaker, AdvaMed president and CEO, made the following comment on the EPA action.
Resource / Ethylene Oxide / Government & Legislative Affairs / Regulatory Affairs
March 1, 2023
Each year in the U.S., ethylene oxide sterilizes 20 billion medical devices, which are critical to preventing serious, even life-threatening, infections.
Blog / Ethylene Oxide / Government & Legislative Affairs
January 31, 2023
A lack of public information persists about sterilizing medical devices with ethylene oxide gas. That's why Scott Whitaker talked with Dr. Lucy Fraiser, a board-certified toxicologist, about the facts.
News / Ethylene Oxide / Regulatory Affairs
January 19, 2023
In a letter to the White House, the Advanced Medical Technology Association (AdvaMed) outlined four key priorities in pending regulations for facilities sterilizing medical devices with ethylene oxide (EtO).
News / Ethylene Oxide
December 14, 2022
AdvaMed's Scott Whitaker sits down on the latest episode of the Medtech POV podcast with toxicologist Dr. Lucy Fraiser to discuss the recent news about ethylene oxide (EtO) used to sterilize medical devices, the nearly non-existent risk to public health from this sterilization method, and what would happen to health care delivery if the chemical were banned as a sterilizer of medical devices and component parts.
FDA: "Very Worried" About Potential Product Shortfalls WASHINGTON, D.C. – "As we wrote to President Biden and have stated for years, the medtech industry welcomes updated regulations governing EtO sterilization because our industry is just as committed to employee and community safety as it is to improving and saving patients’ lives. However, EPA on one hand recognizes the challenges its proposals pose for the sterile medical technologies patients depend on. On the other hand, it dismisses or downplays the challenges. Patients can't afford for the EPA to sweep those concerns under the rug. Our ability to serve patients depends on not only innovating medtech but also supplying safe, sterile medtech on time, in abundance, to healthcare providers when and wherever they need it." # # # Medtech Leaders Testify Before EPA on Safety, Critical Role of Ethylene Oxide Sterilization in Public Health